EXHIBIT 1

FOR IMMEDIATE RELEASE

Contacts:
Mano Mahadeva                                       Alvis Swinney
832.601.6128                                        832.601.6174
mano.mahadeva@usoncology.com                        alvis.swinney@usoncology.com

US Oncology, Inc. Completes Private Placement of $175 Million of Senior
Subordinated Notes

     HOUSTON, Feb. 1, 2002 - US Oncology, Inc. (Nasdaq: USON) today announced it
completed a private placement of $175,000,000 aggregate principal amount of
unsecured senior subordinated notes. The notes bear interest at an annual rate
of 9.625 percent and mature on Feb. 1, 2012.

     The notes are guaranteed on an unsecured senior subordinated basis by the
Company's subsidiaries. The net proceeds of the offering will be used to repay
senior debt and for general business purposes.

     UBS Warburg, Wachovia Securities and Deutsche Banc Alex. Brown were the
joint lead managers for the private placement of the notes.

     US Oncology, headquartered in Houston, is America's premier cancer care
services company. The Company supports the cancer care community by providing
oncology pharmaceutical services, cancer center services, and cancer research
services. US Oncology is affiliated with over 850 physicians operating in over
450 locations, including 77 outpatient cancer centers, in 27 states.

This press release contains forward-looking statements, including statements
that include the words "believes," "expects," "anticipates," "estimates,"
"intends," "plans," "projects," or similar expressions and statements regarding
our prospects. All statements concerning expected financial results, the
benefits of the service line structure, pro forma financial presentations, and
all other statements other than statements of historical fact included in this
press release are forward-looking statements. Although the company believes that
the expectations reflected in such statements are reasonable, it can give no
assurance that such expectations will prove to have been correct. Matters that
could further impact future results and financial condition include the success
of the service line structure, transition of existing practices, expansion into
new markets, reimbursement for healthcare services, government regulation and
enforcement, continued relationships with pharmaceutical companies and other
vendors, increases in the cost of providing cancer treatment services and the
operations of the company's affiliated physician groups. Please refer to the
company's filings with the Securities and Exchange Commission, including its
Annual Report on Form 10-K for 2000 and subsequent SEC filings, for a more
extensive discussion of factors that could cause actual results to differ
materially from the company's expectations.

                                      ###